Development of lecithinized superoxide dismutase as a drug for IPF

Tohru Mizushima

doi:10.2745/dds.28.221

Development of lecithinized superoxide dismutase as a drug for IPF

Tohru Mizushima

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

Original language	English
Pages (from-to)	221-228
Number of pages	8
Journal	Drug Delivery System
Volume	28
Issue number	3
DOIs	https://doi.org/10.2745/dds.28.221
Publication status	Published - 2013

Keywords

Chronic obstructive pulmonary disease
Idiopathic pulmonary fibrosis
Lecithinized SOD
Reactive oxygen species
Superoxide dismutase

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.2745/dds.28.221

Cite this

@article{546f2ce217f74fb4ade49944f555c32e,

title = "Development of lecithinized superoxide dismutase as a drug for IPF",

abstract = "Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.",

keywords = "Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Lecithinized SOD, Reactive oxygen species, Superoxide dismutase",

author = "Tohru Mizushima",

year = "2013",

doi = "10.2745/dds.28.221",

language = "English",

volume = "28",

pages = "221--228",

journal = "Drug Delivery System",

issn = "0913-5006",

publisher = "Japan Society of Drug Delivery System",

number = "3",

}

TY - JOUR

T1 - Development of lecithinized superoxide dismutase as a drug for IPF

AU - Mizushima, Tohru

PY - 2013

Y1 - 2013

N2 - Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

AB - Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are thought to involve lung injury induced by reactive oxygen species (ROS), in particular superoxide anion. The enzyme, superoxide dismutase (SOD) catalyses the dismutation of superoxide anion to hydrogen peroxide. Lecithinized SOD (PC-SOD) has overcome a number of previous clinical limitations of SOD, including low tissue affinity and low stability in plasma. Recent animal studies suggest that PC-SOD is effective for the treatment of IPF and COPD. We are now performing the clinical study of PC-SOD for IPF patients.

KW - Chronic obstructive pulmonary disease

KW - Idiopathic pulmonary fibrosis

KW - Lecithinized SOD

KW - Reactive oxygen species

KW - Superoxide dismutase

UR - http://www.scopus.com/inward/record.url?scp=84940356214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940356214&partnerID=8YFLogxK

U2 - 10.2745/dds.28.221

DO - 10.2745/dds.28.221

M3 - Article

AN - SCOPUS:84940356214

SN - 0913-5006

VL - 28

SP - 221

EP - 228

JO - Drug Delivery System

JF - Drug Delivery System

IS - 3

ER -

Development of lecithinized superoxide dismutase as a drug for IPF

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this